secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001564590-22-019075
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Biosciences Q1 net loss $30.6M; cash $191M funds into 2024
-----------------------------------------------------------------

- Net loss $30.6M in Q1 2022 vs. $11.7M in Q1 2021; R&D spend $25.5M (up from $8.2M).
- Cash & equivalents $191.0M as of March 31, 2022, compared to $219.7M at year-end 2021.
- Initial APEX Phase 2 data for bezuclastinib in AdvSM to be presented at EHA June 2022.
- FGFR2 inhibitor advancing toward IND in H2 2023; ErbB2 mutant selective program announced.
- SUMMIT (NonAdvSM) and PEAK (GIST) trials actively enrolling patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000156459022019075/0001564590-22-019075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000156459022019075/cogt-8k_20220510.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-019075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer